Analysis of ANC recovery from a Phase III study of lipegfilgrastim versus pegfilgrastim in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy

被引：0
|
作者：
Bondarenko, I. [1 ]
Bias, P. [2 ]
Elsaesser, R. [2 ]
Buchner, A. [2 ]
机构：
[1] Dnepropetrovsk Municipal Clin Hosp 4, Dnepropetrovsk, Ukraine
[2] Teva Ratiopharm, Ulm, Germany
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1961
引用
收藏
页码：S434 / S435
页数：2
相关论文
共 50 条
  • [41] Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial
    Norikazu Masuda
    Yutaka Tokuda
    Seigo Nakamura
    Ryutaro Shimazaki
    Yoshinori Ito
    Kazuo Tamura
    Supportive Care in Cancer, 2015, 23 : 2891 - 2898
  • [42] Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support
    Wolff, AC
    Jones, RJ
    Davidson, NE
    Jeter, SC
    Stearns, V
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) : 2392 - 2394
  • [43] Efficacy and Safety of Balugrastim Compared With Pegfilgrastim in Patients With Breast Cancer Receiving Chemotherapy
    Volovat, Constantin
    Gladkov, Oleg A.
    Bondarenko, Igor M.
    Barash, Steve
    Buchner, Anton
    Bias, Peter
    Adar, Liat
    Avisar, Noa
    CLINICAL BREAST CANCER, 2014, 14 (02) : 101 - 108
  • [44] Responses of Blood System to Doxorubicin/Docetaxel Chemotherapy in Patients with Breast Cancer
    Goldberg, V. E.
    Polyakova, T. Yu.
    Popova, N. O.
    Vysotskaya, V. V.
    Simolina, E. I.
    Dudnikova, E. A.
    Goncharova, N. M.
    Belevich, Yu. V.
    Grigor'ev, E. G.
    Goldberg, A. V.
    Dygai, A. M.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2019, 168 (02) : 275 - 279
  • [45] Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer
    Wenzel, C
    Bartsch, R
    Locker, GJ
    Hussian, D
    Pluschnig, U
    Sevelda, U
    Gnant, MF
    Jakesz, R
    Zielinski, CC
    Steger, GG
    ANTI-CANCER DRUGS, 2005, 16 (04) : 441 - 445
  • [46] Responses of Blood System to Doxorubicin/Docetaxel Chemotherapy in Patients with Breast Cancer
    V. E. Goldberg
    T. Yu. Polyakova
    N. O. Popova
    V. V. Vysotskaya
    E. I. Simolina
    E. A. Dudnikova
    N. M. Goncharova
    Yu. V. Belevich
    E. G. Grigor’ev
    A. V. Goldberg
    A. M. Dygai
    Bulletin of Experimental Biology and Medicine, 2019, 168 : 275 - 279
  • [47] Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy
    Eldar-Lissai, Adi
    Cosler, Leon E.
    Culakova, Eva
    Lyman, Gary H.
    VALUE IN HEALTH, 2008, 11 (02) : 172 - 179
  • [48] Economic analysis of prophylactic pegfilgrastim in cancer patients receiving chemotherapy.
    Eldar-Lissai, A
    Cosler, LE
    Lyman, GH
    BLOOD, 2004, 104 (11) : 608A - 608A
  • [49] Effect of 3 mg versus 6 mg pegfilgrastim on the prevention of febrile neutropenia in breast cancer patients receiving docetaxel and cyclophosphamide: a retrospective study
    Zhang, Zhisheng
    Li, Huan
    Zhang, Jiacheng
    Ye, Xuan
    Liu, Hongyue
    Zhai, Qing
    Yu, Bo
    Du, Qiong
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (05) : 5310 - 5315
  • [50] Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy
    Yang, Bing-Bing
    Kido, Anna
    Shibata, Atsuko
    PHARMACOTHERAPY, 2007, 27 (10): : 1387 - 1393
12345